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Abstract
Introduction: England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent
equivalent (PCV13), partly based on projections from mathematical models of the long-term impact of such a switch
compared to ceasing pneumococcal conjugate vaccination altogether.
Methods: A compartmental deterministic model was used to estimate parameters governing transmission of infection and
competition between different groups of pneumococcal serotypes prior to the introduction of PCV13. The best-fitting
parameters were used in an individual based model to describe pneumococcal transmission dynamics and effects of various
options for the vaccination programme change in England and Wales. A number of scenarios were conducted using (i)
different assumptions about the number of invasive pneumococcal disease cases adjusted for the increasing trend in
disease incidence prior to PCV7 introduction in England and Wales, and (ii) a range of values representing serotype
replacement induced by vaccination of the additional six serotypes in PCV13.
Results: Most of the scenarios considered suggest that ceasing pneumococcal conjugate vaccine use would cause an
increase in invasive pneumococcal disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease.
However, the size of this reduction largely depends on the level of competition induced by the additional serotypes in
PCV13. The model estimates that over 20 years of PCV13 vaccination, around 5000–62000 IPD cases could be prevented
compared to stopping pneumococcal conjugate vaccination altogether.
Conclusion: Despite inevitable uncertainty around serotype replacement effects following introduction of PCV13, the model
suggests a reduction in overall invasive pneumococcal disease incidence in all cases. Our results provide useful evidence on
the benefits of PCV13 to countries replacing or considering replacing PCV7 with PCV13, as well as data that can be used to
evaluate the cost-effectiveness of such a switch.
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Introduction
Prior to the introduction of Prevnar 7TM, the 7-valent
pneumococcal conjugate vaccine (PCV7), in England and
Wales, Streptococcus pneumoniae was responsible for about 6,000
annual cases of invasive pneumococcal diseases (IPD), with
presentations such as meningitis, bacteraemia, sepsis and
pneumonia. PCV7 provides protection against 7 serotypes (4,
6B, 9V, 14, 18C, 19F and 23F) among more than 90
pneumococcal serotypes identified so far. It was introduced
into the UK routine childhood immunisation programme in
September 2006 for infants at 2, 4 and 13 months with a catch
up to children under two years of age. Introduction was
informed by a dynamic transmission model parameterised using
IPD data following PCV7 introduction in the United States.
The model predicted elimination of vaccine-type (VT) IPD in
the long term with limited serotype replacement, hence leading
to sustained reduction in overall IPD in all age groups [1].
However, the post-PCV7 experience in England and Wales has
shown more aggressive serotype replacement and less impact on
overall IPD than reported in the US, likely due to differences
between countries in IPD surveillance systems [2,3]. An updated
analysis using a transmission dynamic model incorporating IPD
data from the first three years of the PCV7 programme in
England and Wales predicted that in the longer term the
reduction in VT IPD due to PCV7 would be largely (though
not fully) negated by serotype replacement [4]. In April, 2010,
Prevnar 13TM (PCV13) covering extra six serotypes (1, 3, 5, 6A,
7F and 19A) replaced PCV7 in the UK (with no catch-up),
sales of PCV7 in the United Kingdom (UK) having been
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e39927
discontinued. Those infants with an incomplete schedule with
PCV7 received the remaining doses with PCV13. Hence it is
important to understand the likely range of possible short-term
effects of PCV13 on disease caused by different serotypes
against a backdrop of serotype replacement following PCV7
introduction, as well as its longer term effect on overall IPD
incidence.
Here we describe an extension of our previous modelling work
in order to address these questions. We use a hybrid modelling
approach, combining an enhanced version of the previously
developed compartmental deterministic model [1,4] and its
individual based representation to estimate the long-term effect
on IPD cases in England and Wales. Two policy options were
evaluated: (i) replacing PCV7 by PCV13, and (ii) discontinuing
PCV vaccination altogether. Continuing use of PCV7 was not
evaluated since the vaccine is no longer available in the UK
market. The model results were used to inform the decision on
introducing PCV13 in England and Wales in 2011.
Materials and Methods
Data
Key model parameters governing transmission and competi-
tion between serotypes were determined by fitting to the same
epidemiological data, as was done in our previously published
model [4]. Data used for this purpose were serotype-specific
pneumococcal carriage prevalence acquired from the longitudi-
nal nasopharyngeal swab study conducted in England between
2001 and 2002 [5], trend adjusted serotype specific number of
IPD cases between 2005/06 and 2008/09 [2], population
mixing information based on a UK contact survey [6], and
monthly PCV7 coverage for each birth month [4]. Serotype-
specific data were stratified into three groups (as opposed to two
in the previous model): the seven serotypes in PCV7 (4, 6B, 9V,
14, 18C, 19F, and 23F; hereafter ‘‘VT1’’ types), the five
additional serotypes in PCV13 excluding serotype 1 (3, 5, 6A,
7F, and 19A; ‘‘VT2’’) and the remaining serotypes in neither
vaccine (‘‘NVT’’). Serotype 1 was excluded as in previous
modelling studies [3] as it has shown large secular changes in
incidence in the UK that are unrelated to PCV7 introduction.
S. pneumoniae in IPD cases was restricted to those identified by
culture [2]. The monthly uptake of PCV13 was assumed to be
the same as it has been for PCV7.
IPD incidence has been increasing in the years prior to PCV7
introduction, likely reflecting improved ascertainment [4,7]. For
the purposes of estimating parameters governing vaccine impact,
we assumed that this trend in IPD has continued for the three
years post-PCV7 introduction which was included for model
fitting. Three scenarios were used (as previously described [4]),
using the midpoint estimate, lower and upper limits of the 95%
confidence intervals of the trend analysis and are respectively
referred to as ‘‘point’’, ‘‘lower’’, and ‘‘upper’’ scenarios in the
following.
Transmission Models
Two types of pneumococcal transmission dynamical models
were developed: a deterministic compartmental model to estimate
model parameters using the data described in the previous section,
and an analogous individual based model to simulate effects of
introducing PCV13 or stopping PCV vaccination entirely.
Parameters estimated from the deterministic model were used as
inputs for the individual based model. The individual based model
was used to implement the heterogeneous vaccine/dose/birth
cohort information in those individuals who started vaccination
with PCV7 but subsequently switched to PCV13 either post dose 1
or post dose 2 during the immunisation course. This was done
because the multitude of possible vaccine status and dose
combinations is too complex to capture in a compartmental
model framework.
Model Structure – Movement between Compartments
Individuals in the population belong to one of eight compart-
ments according to the nature of serotypes they carry in their
nasopharynx (deemed an infection): susceptible to any infection
(hereafter ‘‘Susc’’), infected with either VT1, VT2 or NVT
serotypes, infected with serotypes from two groups (‘‘VT1VT2’’,
‘‘VT1NVT’’, ‘‘VT2NVT’’) and infected with serotypes from all
three groups (‘‘All’’). This is shown graphically in Figure 1.
Individuals can clear the infection according to age-dependent
clearance rates [4]. Clearance rates were assumed to be similar for
all infections (VT1, VT2, and NVT).
Three parameters (l1, l2, and l3) in Figure 1 respectively
represent the transmission probabilities per close contact for the
corresponding three pneumococcal serotype groups (VT1, VT2
and NVT). Nine parameters (C1, …, C9) represent the propensity
for competition between three serotype groups: individuals
carrying an infection from one serotype group are partially
protected against acquiring an infection from another serotype
group according to the value of corresponding competition
parameter (which ranges between 0 for complete protection and
1 for no competition and no restrictions on coexistence of different
serotype groups in individual hosts). For example, individuals
carrying VT1 are protected from acquiring VT2 by having the
force of infection, l3, reduced by the competition parameter C1
(see Figure 1).
The culture method used for identifying serotypes in carriage
samples has poor sensitivity to multiple carriage [8]. Therefore,
the competition parameters can only be estimated by fitting the
model using post vaccination data showing the magnitude of
replacement of VT IPD cases with NVT IPD cases.
1. As in Choi et al. [4], the magnitude of competition induced by
carrying the serotypes in PCV7 against other serotype groups
(here, C1 and C2) can be estimated by making use of pre- and
post- PCV7 vaccination IPD data.
2. Similarly, C3 cannot be estimated since post PCV13
vaccination data was not available at the time of the analysis.
However, this parameter, governing competition between
NVT and VT2 is highly influential in terms of determining
the replacement effects following vaccination with PCV13. For
this reason, we explored the whole parameter range by
employing three scenarios (C3= 0, 0.5, and 1).
3. Competition parameters C4 and C5 represent the protection
that individuals carrying VT2 or NVT have against acquiring
VT1. These parameters do not alter the prevalence of VT2 or
NVT after PCV7 introduction since with the elimination of
VT1 carriage the respective compartments of multiple carriage
disappear. Hence C4 and C5 cannot be estimated using the
post-PCV7 data but also the post vaccination epidemiology is
insensitive to them. For similar reasons, the competition
parameters C6, C7, C8 and C9 also have no significant effect
on the post PCV7 and PCV13 epidemiology. We fixed all these
competition parameters (C4 to C9) at 0.5.
Fitting Procedures - Post-PCV7 Data
Model parameters governing transmission and coexistence
between different groups of serotypes within individuals were
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estimated by fitting the deterministic model to IPD data in both
the pre-PCV7 and post-PCV7 periods in the following way:
1. The model’s goodness of fit (measured in terms of the Poisson
deviance between the prevalence of pneumococcal carriage
predicted by the model and reported in the carriage study) is
calculated for six age groups among the three serotype groups
assuming that the culturing processes only detect the most
dominant serogroups amongst the serotypes carried. The order
of this dominancy is assumed to follow: VT1.VT2.NVT.
2. The propensity to develop invasive disease given carriage for
three serotype groups and 16 age groups is calculated using the
trend-adjusted number of IPD cases in 2005/06, assuming
carriage prevalence has been stable since 2000/01.
3. The goodness of fit between the number of IPD cases
predicted by the model (which is determined by the predicted
carriage prevalence and the calculated propensity to develop
invasive disease given carriage) and trend-adjusted post-
PCV7 data (measured in terms of Poisson deviance) is
calculated.
4. A simplex algorithm determining the minimal overall deviance
(FMINSEARCH in MATLABTM) was employed to find the
optimal parameter sets for the different scenarios.
Figure 1. Flow diagram showing the relationship between different states representing carriage of different groups of
pneumococcal serotypes in the models used.
doi:10.1371/journal.pone.0039927.g001
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Individual Based Model
The dynamics of pneumococcal transmission and the likely
impact of changing the valency of the PCV vaccination
programme were modelled in an individual based framework
that exactly reproduced the deterministic model. The simula-
tions were run with four time steps for each month, with 100
age cohorts from 0 to 99 year olds. As a consequence, the total
population size is 48 million, comprising of 10,000 individuals
in each of 4,800 birth cohorts. As in the deterministic model
each age cohort is weighted based on the population structure
of England and Wales in 2006 to estimate the force of infection
for three serotype groups at each time step [4]. Hence the
overall weighted population size gives a realistic representation
of the number of IPD cases in England and Wales. At each
time step, 10,000 individuals in the last weekly age cohort are
removed and replaced with 10,000 susceptible individuals in the
first weekly age cohort, representing a simple birth and death
process [4].
Acquisition and loss of infection, and loss of vaccine protection
occur as stochastic processes, with their probabilities determined
by the force of infection, duration of infection, and duration of
vaccine protection, respectively. Each scenario is repeated ten
times in order to estimate the stochastic uncertainty arising from
these processes.Only ten repetitions were necessary as the large
population size (48 million) limited stochastic variation between
repetitions and only their mean is reported here.
Vaccination Scenarios in the Individual Based Model
The effect of each dose of the PCV vaccination programme in
the individual based model is shown in Figure 2:
1. Individuals who receive one dose when above the age of one
year are fully protected. Those who receive one dose under the
age of one year are only partially protected.
2. Individuals who receive two or more doses are fully protected.
3. Individuals who lose vaccine protection by waning are only
partially protected.
4. If individuals who are partially protected receive another dose,
they then become fully protected.
5. PCV7 vaccination begins in September 2006 and is either
changed to PCV13 or stopped in April 2010.
6. When PCV7 is replaced with PCV13, individuals who were
scheduled to receive the remaining PCV7 doses receive PCV13
instead and get protection against extra serotypes included in
PCV13. For example, if an infant received the first dose with
PCV7 and the second dose with PCV13, the infant gets full
protection against PCV7 serotypes but only partial protection
against extra serotypes in PCV13.
Vaccine Efficacy Against Disease Development and
Infection
The duration of vaccine protection against acquisition of
carriage and disease development is assumed to be 5 years [4].
The degree of vaccine protection for vaccinated individuals against
acquiring VT1 and VT2 carriage is assumed to be 52% for fully
protected individuals and 26% for partially protected individuals
[4]. A similar figure was estimated by Rinta-Kokko et al. [9].
Vaccine efficacy against developing IPD is assumed to be 100%
for both partially and fully protected individuals, based on fitting
to data and as assumed in previous studies [1,4]. PCV7 and
PCV13 were assumed to be similar in those aspects.
Results
Fitting
Table 1 presents the best fitting pairs of the competition
parameters, C1 and C2, representing the protective effect of
carrying VT1 infections against acquiring infections with serotypes
belonging to VT2 and NVT respectively. In all scenarios,
protection against both serogroups exceeds 58%.
For all three scenarios of data adjustment for trend, the model
fitted the number of IPD cases as observed in England and Wales
well (Figure 3). In all these scenarios vaccination with PCV7 from
September 2006 resulted in a rapid reduction in PCV7 serotypes
and a concurrent increase in both VT2 and NVT serotypes.
Long-term Effects on IPD Cases
Stopping PCV vaccination altogether in April 2010 is predicted
to cause a rebound in the number of IPD cases to the pre-PCV7
equilibrium due to an increase in VT1 IPD as well as decreases in
both VT2 and NVT IPD (Figure 4). On the other hand, a
reduction in the number of IPD cases due to VT2 serotypes is
predicted if PCV13 is introduced from April 2010, eventually
leading to elimination of both VT1 and VT2 serotypes, even
though there is no immediate reduction in VT2 IPD cases among
unvaccinated individuals in the first few years due to ongoing
replacement effects from PCV7 in the population. With PCV13
introduction, the number of NVT IPD cases increases regardless
of the value of the competition parameter, C3, because of the
ongoing serotype replacement effect caused by PCV7 introduc-
tion. However, stronger competition (lower C3) would cause much
larger increases in the number of NVT IPD cases (Figure 4) which
leads to a smaller reduction in overall IPD (Figure 5). The
reduction in the overall number of IPD cases with the introduction
of PCV13 in all scenarios considered is due to the lower case:
carrier ratios of non-PCV13 serotypes compared to those in VT1
and VT2 serogroups in elderly age groups where the most IPD
cases occur (Figure 6).
The baseline epidemiological year for calculating the impact of
the change in vaccination policy away from PCV7 is assumed to
be 2009/10, since PCV13 was only implemented three months
before the end of 2009/10. Table 2 presents the difference in
model projections of the cumulative and annual numbers of IPD
cases after PCV13 introduction over the 20 years from baseline to
the epidemiological year 2029/30, compared to no PCV
vaccination. Introduction of PCV13 is estimated to reduce the
number of IPD cases in the subsequent 20 years by 5,000 to
62,000 compared to the scenario of discontinuing PCV7. The
difference in the annual number of IPD cases in the epidemio-
logical year 2029/30 ranges from 180 (6% of the number
predicted without PCV vaccination) to 3700 (42%) compared to
the epidemiological year 2009/10 depending on the scenarios
governing the IPD trend and the value for the competition
parameter C3.
Discussion
PCV13 replaced PCV7 in the UK’s vaccination schedule in
April 2010 following the manufacturer’s decision to cease
marketing PCV7 in the UK and only to offer PCV13. At the
time of the analysis neither information about multiple carriage
episodes nor data on post PCV13 IPD replacement was available.
Such information is needed to estimate the competition parameter
determining the protection individuals carrying VT2 receive
against acquiring NVT infections and the consequent level of
NVT replacement expected following the introduction of PCV13.
Modelling Long-Term Effects of Prevnar13 in E&W
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However, we were able to capture this uncertainty and show that
even in the case of strong competition between those serotype
groups, the corresponding level of serotype replacement is unlikely
to offset the benefits in reduction in IPD, which is mainly due to
the lower invasiveness of the NVT serotype group among over 65
year olds where the majority of IPD cases occur (Figure 6).
The indirect impact of pneumococcal conjugate vaccines is
governed by two opposing effects. The beneficial effect is the
reduction in the number of vaccine related IPD cases among
unvaccinated individuals in the population due to the reduction in
pneumococcal carriage and transmission in vaccinated individuals.
The detrimental effect is the replacement of vaccine types with
non vaccine types: removing the targeted serotypes leaves open an
ecological niche for other serotypes to colonise. When there is little
propensity for different serotypes to coexist in the host then it is
assumed that there is competition between them to colonise the
nasopharynx, so carrying one serotype has a protective effect
against acquiring another serotype. The stronger the effect of this
competition (with a consequent lower propensity to coexist), the
more likely it is that individuals will acquire NVT serotypes
Figure 2. Flow diagram showing how vaccination status of individuals is tracked in the model, based on the number of doses
received and waning of vaccine protection. Individuals who receive one dose while above the age of one year are fully protected. Those who
receive their first dose under the age of one year are only partially protected. Those who receive 2 or more doses receive full protection. Those who
lose vaccine protection move to the next less well protected group.
doi:10.1371/journal.pone.0039927.g002
Table 1. Competition parameters C1 and C2 for individuals carrying VT1 serotype infections who get protection against acquiring
carriage due to VT2 and NVT serotypes.
C3 0 0.5 1
Trend Point Lower Upper Point Lower Upper Point Lower Upper
C1 0.25 0.20 0.37 0.29 0.21 0.40 0.27 0.20 0.39
C2 0.02 0.00 0.20 0.26 0.17 0.41 0.17 0.08 0.33
C3 (the competition parameter representing the protective effect of carrying VT2 against acquiring NVT serotypes) takes values of 0, 0.5 and 1 in different scenarios. The
IPD data were adjusted using three scenarios about the year-on-year increase in the number of IPD cases based on pre-PCV7 trends.
doi:10.1371/journal.pone.0039927.t001
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following vaccination because competition induced by vaccine
serotypes is reduced. The existence of such competition is widely
accepted [3] and is supported by the increase in NVT IPD cases in
England and Wales since PCV7 introduction [2]. Using mathe-
matical models we found that the parameters governing compe-
tition between serotypes in PCV13 and other serotypes is crucial
for estimating replacement following its introduction and thereby
the overall effects on pneumococcal invasive disease.
The mechanisms driving competition and co-existence between
the various pneumococcal serotypes are poorly understood but
play a crucial role in determining the effects of vaccination on the
transmission dynamics of pneumococcal carriage and disease. The
modelling approach we implemented accounts for both these
aspects with a mechanistic rather then a causal representation of
competition between serotypes. The model promotes co-existence
of serotypes trough implicitly assuming serotype group specific
immunity for the duration of carriage and thus providing an
ecological niche for other serotype groups. Hence, the model is not
structurally neutral [10]. Despite this potential shortcoming, by
fitting just a few parameters (competition and propensity to cause
disease when colonised) the model was able to closely reproduce
the observed disease due to VT1, VT2 and NVT serotypes before
introduction of PCV13 as well as the observed herd immunity and
non-vaccine-type replacement in the PCV7 era between 2005/6
and 2008/09. Hence, in the absence of further knowledge (in
particular of observed post PCV13 replacement) this model
suggests a likely range of impact following the change in
pneumococcal vaccination policy in April 2010 in the UK.
In this paper, we present a novel model to estimate a priori the
effect on IPD of replacing PCV7 vaccination with pneumococcal
vaccines of higher valency (PCV13) that captures the transmission
dynamics of herd immunity and serotype replacement. In order to
capture the effect of giving different vaccines (PCV7 and PCV13)
to the same individuals, we used an individual based modelling
framework that allowed detailed characteristics of each individual
within a model to be tracked. However, the computational
requirements of this choice of model structure make it challenging
to estimate model parameters in a complex dynamical system.
Hence we used a hybrid approach, with a deterministic
compartmental transmission dynamic model used to estimate
Figure 3. Comparison between the annual number of IPD cases reported pre and three years post- PCV7 introduction, with fitting
results based on the model when C3 (representing the protective effect of carrying VT2 serotypes against infection with NVT) is
fixed at 0.5. The number of IPD cases has been adjusted using the upper, lower and medium scenarios for the secular trend in IPD prior to PCV7
introduction.
doi:10.1371/journal.pone.0039927.g003
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relevant model parameters using pre-PCV7 carriage data, trend-
adjusted IPD data between pre- and post-PCV7 periods, age-
dependent mixing and PCV7 coverage. Once these parameters
had been estimated, we used an individual based model in order to
measure the effects of two alternative vaccination programmes on
the number of annual IPD cases.
One encouraging result is that all the scenarios considered in
this study suggest reductions in the overall number of IPD cases
following PCV13 introduction, though of varying magnitude.
This predicted reduction in the overall number of IPD cases
following PCV13 introduction is due to the lower propensity to
develop invasive disease given carriage of non-PCV13 serotypes
in elderly age groups where most of the IPD cases occur.
Similar results were found in a UK study predominantly in
children [11]. Furthermore, our estimates are likely to be
conservative since we do not account for the highly invasive
serotype 1. The scenario we examine that predicts the largest
reduction in the number of IPD cases following PCV13
introduction (compared to stopping PCV vaccination altogether)
occurs in the absence of competition between the additional
serotypes in PCV13 and non-PCV13 serotypes which would
have caused no serotype replacement (see Table 2), reflecting an
assumption that there is perfect coexistence between VT2 and
NVT serotypes in individual hosts. This appears unlikely since
the protective effect of carriage on heterologous acquisition of
carriage was found to be high for various settings [4,12]. If this
also holds true for the additional serotypes in PCV13, then the
effect of PCV13 introduction on pneumococcal carriage will be
largely negated in older age groups by the replacement of VT2
serotypes with NVT serotypes, as was the case following PCV7
introduction in England and Wales [4]. However, PCV13 may
still be beneficial in terms of IPD reduction since the NVT
serotypes have a lower propensity to develop invasive disease
compared to VT2 serotypes.
Many high income countries with existing immunisation
programmes using PCV7 are replacing or considering replacing
Figure 4. Model projections of the long-term effects of either stopping pneumococcal conjugate vaccination or replacing PCV7
with PCV13 on April 2010 on the number of IPD cases caused by VT1, VT2, and NVT serotype groups in England and Wales over 35
years since the introduction of PCV7. C3 (representing the protective effect of carrying VT2 serotypes against infection with NVT) takes the
values 0, 0.5, and 1 in different scenarios. Filled circles show results with C3= 0.5 and the error bars represent results with C3= 0 or 1. Scenarios are
presented in terms of IPD data being adjusted by high, low and medium estimates for the secular trend in IPD prior to PCV7 introduction.
doi:10.1371/journal.pone.0039927.g004
Figure 5. Proportional changes in the number of overall IPD cases following either stopping pneumococcal conjugate vaccination
or replacing PCV7 with PCV13 on April 2010. PCV7 is replaced with PCV13 six years after PCV7 introduction. C3 (representing the protective
effect of carrying VT2 serotypes against infection with NVT) takes the values 0, 0.5, and 1 in different scenarios. Filled circles show results with C3 = 0.5
and the error bars represent results with C3= 0 or 1. IPD data were adjusted based on the high, low and medium estimates for the secular trend in
IPD prior to PCV7 introduction (corresponding to the upper and lower limits of the error bars as well as the points).
doi:10.1371/journal.pone.0039927.g005
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PCV7 with PCV13 due to its increased serotype coverage.
However, this change will not eliminate the potential for serotype
replacement since most of the pneumococcal serotypes causing
IPD are not present in PCV13 either. Hence the medium and long
term effects of using PCV13 in the context of pre-existing use of
PCV7 are still largely unknown. Several models have been
developed to estimate this effect [13–15]. However existing
published models are static; hence they make assumptions about
serotype replacement following PCV13 introduction that are not
informed by the dynamics of intertype competition. In contrast we
here present a dynamic model capturing the possible range of
values for parameters governing serotype replacement.
This study uses dynamic (deterministic and individual based)
models to estimate the direct and indirect effects of replacing an
existing infant PCV7 vaccination programme with a higher
valency vaccine such as PCV13. The transmission model allows
more realistic estimation of dynamic effects (indirect protection
and serotype replacement) of pneumococcal conjugate vaccines
than static models, even when the latter are adjusted using a
‘‘dynamic approximation’’ technique [16]. We find that in the
Figure 6. Propensity for individuals carrying pneumococcal serotypes in three serogroups (VT1, VT2 and NVT) among 16 age
groups to develop disease. The ratios are obtained from the scenario using 0.5 as the competition parameter, C3, and the IPD cases adjusted
using the point estimate of the adjustment for the increasing trend in such cases (shaded areas show the ratios estimated using the lower and upper
boundaries of its 95% CIs).
doi:10.1371/journal.pone.0039927.g006
Table 2. Model estimates of the amount of prevented cases by introducing PCV13 compared to discontinuing PCV7.
Competition C3=0 C3=0.5 C3=1
Trend Point Lower Upper Point Lower Upper Point Lower Upper
Cumulative difference
in cases over 20 years
16,664 5,346 28,114 39,324 30,092 49,394 51,231 43,915 62,851
Annual difference 928 182 1,675 2,213 1,603 2,927 2,934 2,397 3,700
The analysis is shown for both the cumulative difference in cases between 2009/10 to 2029/30 and the difference 20 years after the change in policy (2029/30).
doi:10.1371/journal.pone.0039927.t002
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short term, replacement of PCV7 with PCV13 is not likely to bring
an immediate rapid reduction in overall IPD cases, because
replacement of VT1 serotypes with VT2 and NVT serotypes is still
progressing among unvaccinated individuals (Figure 7). However
in the long term, a substantial reduction in IPD cases is likely to
occur.
Conclusions
In this study we estimated parameters governing the effect of
introducing PCV13 to replace PCV7 or of discontinuing
pneumococcal conjugate vaccination through parsimonious
dynamic models. Prior to robust data on replacement induced
by vaccination with PCV13 and in the absence of information
about multiple carriage episodes, a key aspect of the impact of
the introduction of PCV13, serotype replacement from the
reduced competitive effect of the six additional vaccine
serotypes, could not be estimated. However, we show that the
possible range of the replacement effect –although substantial- is
unlikely to span scenarios where introduction of PCV13
becomes less beneficial than the alternative option of discon-
tinuing conjugate vaccination. Data on multiple carriage would
help to reduce the uncertainty of such a priori estimations but
would be difficult to obtain because of the large sample size
needed to adequately estimate age-dependent carriage preva-
lence for the compartments of multiple carriage defined in the
model. Hence our results provide useful evidence on the
possible benefits of PCV13 to countries replacing or considering
replacing PCV7 with PCV13, as well as data that can be used
to evaluate the cost-effectiveness of such a switch.
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